TrialJournal of clinical immunology2021

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study.

John T Anderson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.